Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
2(22%)
Results Posted
20%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph early_phase_1
2
22%
Ph phase_1
1
11%
Ph phase_3
1
11%
Ph phase_2
4
44%

Phase Distribution

3

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
2(25.0%)
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Active, not recruiting2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Early Phase 12 (25.0%)
Phase 11 (12.5%)
Phase 24 (50.0%)
Phase 31 (12.5%)

Trials by Status

active_not_recruiting222%
completed556%
terminated111%
withdrawn111%

Recent Activity

2 active trials
Showing 5 of 9
active_not_recruitingearly_phase_1

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

NCT04147494
active_not_recruitingphase_3

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

NCT03582774
withdrawnphase_2

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

NCT05034562
completedphase_1

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

NCT04216134
completed

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

NCT03857087
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04147494Early Phase 1

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Active Not Recruiting
NCT03582774Phase 3

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

Active Not Recruiting
NCT05034562Phase 2

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Withdrawn
NCT04216134Phase 1

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

Completed
NCT03857087

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

Completed
NCT04050215Phase 2

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

Completed
NCT03463889Phase 2

Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer

Terminated
NCT04282824Early Phase 1

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer

Completed
NCT03515577Phase 2

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9